upifitamab rilsodotin

Upifitamab rilsodotin (UpRi, XMT-1536) is an antibody-drug conjugate from Mersana Therapeutics that targets NaPi2b, a sodium-dependent phosphate transporter heavily expressed on ovarian and lung tumor cells. The first-in-human Phase 1 trial NCT03319628 enrolled 523 patients across ovarian cancer and NSCLC, and the program was once Mersana's lead asset with Fast Track designation in platinum-resistant ovarian cancer [1][2]. The story turned on July 27, 2023, when the registrational single-arm Phase 2 UPLIFT trial (NCT03942536) in platinum-resistant ovarian cancer missed its primary endpoint - investigator-assessed ORR of 15.6% (95% CI 10.0%-22.7%) in the NaPi2b-high (TPS ≥75%) population, with the lower CI bound failing to exclude the 12% single-agent chemotherapy bar [3][9]. Mersana then restructured, paused the program, and pivoted resources to next-generation ADCs (XMT-1660/emi-le, XMT-2056) [4][5]. Treat this node as a post-failure asset, not an active contender.

Investigational, never approved, and no longer under active development for ovarian cancer. The active node NCT03319628 is a Phase 1 dose-escalation and expansion study now listed as active, not recruiting after enrolling 523 patients across NaPi2b-expressing solid tumors [1]. FDA granted Fast Track designation in platinum-resistant ovarian cancer in 2021. The key context sits outside this trial: UPLIFT (NCT03942536) was the single-arm Phase 2 designed to support accelerated approval in ovarian cancer [9]. On July 27, 2023, Mersana disclosed that UPLIFT missed its primary endpoint of investigator-assessed confirmed ORR in the NaPi2b-positive (TPS ≥75%) subset: 15.6% (95% CI 10.0%-22.7%; n≈141), with secondary readouts of 10.2% in NaPi2b-low (n=127) and 13.1% in the ITT population (n=268) [3]. The lower bound of the primary endpoint CI did not exclude the 12% historical control for single-agent chemotherapy, ending the registrational path [3][9]. Mersana announced a workforce reduction and program reprioritization the same day [4]. By the 2024 10-K (filed March 2025), Mersana had shifted its forward narrative to next-generation ADCs (emi-le/XMT-1660, XMT-2056) and away from UpRi as a near-term commercial driver [5]. No expected readout, no registrational path active.

NaPi2b (SLC34A2) is a sodium-dependent phosphate transporter that moves phosphate across the cell membrane. It is expressed at modest levels in normal lung and ovary, and upregulated in a majority of high-grade serous ovarian cancers and a meaningful fraction of non-squamous NSCLC - published estimates put strong membranous expression in roughly 65% of high-grade serous ovarian tumors, though the figure is sensitive to the IHC cutoff used; UPLIFT used a tumor proportion score (TPS) ≥75% to define 'NaPi2b-positive' [6][3]. Upifitamab rilsodotin is built on Mersana's Dolaflexin platform: an antibody recognizing NaPi2b is linked to about 10-12 copies of an auristatin-class microtubule poison (DolaLock), with a controlled-release linker designed to drop the payload once inside the tumor cell. The pitch was a high drug-to-antibody ratio with the linker stability needed to avoid systemic toxicity. The mechanism is biologically sound on paper, but the validation case is weak: in UPLIFT, the NaPi2b-high subset (ORR 15.6%) was only modestly better than the NaPi2b-low subset (ORR 10.2%), meaning the IHC cutoff did not meaningfully enrich for responders [3]. The broader question - whether NaPi2b-targeted cytotoxic delivery beats existing ovarian options like the folate-receptor ADC mirvetuximab soravtansine (Elahere) - was answered with a 'no' in the registrational dataset [3][7].

NCT03319628 is the long-running Phase 1 first-in-human, dose-escalation plus expansion design that grew to 523 patients across ovarian cancer, NSCLC, and other NaPi2b-expressing solid tumors [1]. Primary endpoints were MTD/RP2D and safety, with response rate and duration as secondary readouts. That design was appropriate for the question being asked at the time. The harder verdict belongs to UPLIFT (NCT03942536, also ENGOT-Ov67/GOG-3048), the single-arm Phase 2 in platinum-resistant ovarian cancer that Mersana was running in parallel as the registrational study, with investigator-assessed confirmed ORR in NaPi2b-positive (TPS ≥75%) patients as the primary endpoint and a target of excluding a 12% ORR historical control for single-agent chemotherapy [3][9]. UPLIFT's design carried two known structural risks: a single-arm accelerated-approval pathway with no comparator in a space where mirvetuximab soravtansine was already establishing a benchmark, and reliance on an IHC-based NaPi2b cutoff whose predictive validity had not been rigorously prospectively confirmed. Both risks materialized - the response rate in the biomarker-selected population (15.6%, lower 95% CI bound 10.0%) was not high enough to clear the chemotherapy bar, and the FDA's overall posture on single-arm accelerated approvals had tightened by 2023 [3][4]. The Phase 1 NSCLC expansion cohorts produced single-agent activity but no signal strong enough to support a separate registrational program in lung cancer, and Mersana did not advance UpRi into a randomized NSCLC study.

Our model estimates an 11% chance this drug is eventually approved. That starting point comes from the historical approval rate for Phase 2 drugs in this area, which is about 13%. The estimate is nudged up by larger-than-typical enrollment and a non-randomized trial design, but pulled back by the sponsor's thin approval record and weak earlier-phase results. The remaining factors fall close to average, so they leave the final number near where it started.

Efficacy risk has already materialized. UPLIFT delivered an investigator-assessed ORR of 15.6% (95% CI 10.0%-22.7%) in the NaPi2b-positive (TPS ≥75%) platinum-resistant ovarian cancer population - the lower bound of the confidence interval did not exclude the 12% historical control for single-agent chemotherapy [3][9]. The biomarker hypothesis - that high NaPi2b IHC expression would enrich for responders - failed in the data (15.6% in NaPi2b-high vs 10.2% in NaPi2b-low; modest delta), which is a deeper problem than a missed numeric endpoint because it undercuts the entire targeting rationale [3]. Safety risk is secondary now but historically included ADC-class toxicities like thrombocytopenia and pneumonitis, which constrained dosing during escalation. Competitive risk is severe: mirvetuximab soravtansine (Elahere) received accelerated approval in 2022 and full approval in 2024 for folate-receptor-alpha-positive platinum-resistant ovarian cancer, occupying the post-platinum slot that UpRi was aiming for, with a head start of years and a positive Phase 3 confirmatory dataset [7]. Commercial risk now collapses into existential risk for the asset itself - Mersana's 2024 10-K reflects $134.6M in cash, cash equivalents and marketable securities at year-end 2024, with stated runway into 2026 and a strategic focus on next-generation ADCs rather than funding another large UpRi trial [5][8].

Noise, not signal, in its current form. The interesting question is no longer 'will upifitamab rilsodotin get approved' - it almost certainly will not in the configuration tested - but 'does the asset get out-licensed, divested, or quietly shelved.' Mersana's 2024 10-K reports $134.6M cash with runway into 2026 and a 2024 net loss of $69.2M, which gives the company about 18-24 months of breathing room before another financing or strategic move is forced [5]; the strategic posture in that filing and subsequent 8-Ks points to emi-le/XMT-1660 and XMT-2056 as the forward platform, with UpRi treated as legacy [5][8]. The data point that would change this read: a credible biomarker reanalysis identifying a responder subset (for example, a defined NaPi2b expression cutoff combined with histology or prior-therapy stratification) published in a peer-reviewed journal or presented at SGO/ASCO with response rates north of 25% in a clean population. Absent that, this node should be watched for divestiture announcements rather than clinical readouts. Check back if Mersana's quarterly filings disclose an out-licensing transaction or if a partner picks up the asset for a non-ovarian indication where NaPi2b biology may behave differently - the Phase 1 NSCLC expansion produced single-agent activity but Mersana did not advance to a randomized study, so any lung-cancer revival would require a partner with conviction in the target. The broader takeaway for NaPi2b as a target: still open, but no longer obviously a winner.